Regeneron Pharmaceuticals, Inc.
Regeneron Reports Strong Q2 2026 Financial Results with Revenue Growth and Product Sales Increases
Summary
Regeneron Pharmaceuticals, Inc. announced its financial and operating results for the second quarter of 2026, reporting a 17% increase in total revenues to $4.3 billion. Net product sales for Dupixent increased by 38% to a new all-time high of $6.0 billion, EYLEA HD net sales increased by 52% to $596 million, and Libtayo net sales increased by 30% to $489 million. The company also fully repaid the Sanofi Development Balance, which will no longer reduce Sanofi collaboration revenue starting in the third quarter. Regeneron provided updated financial guidance for 2026, reflecting its strong performance and outlook.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement